Ganglion cysts are soft tissue swellings occurring most commonly in the hand or wrist. Apart from swelling, most cysts are asymptomatic. Other symptoms include pain, weakness, or paraesthesia. The two main concerns patients have are the cosmetic appearance of the cysts and the fear of future malignant growth. It has been shown that 58% of cysts will resolve spontaneously over time. Treatment can be either conservative or through surgical excision. This review concluded that nonsurgical treatment is largely ineffective in treating ganglion cysts. However, it advised to patients who do not surgical treatment but would like symptomatic relief. Compared to surgery, which has a lower recurrence rate but have a higher complication rate with longer recovery period. It has been shown that surgical interventions do not provide better symptomatic relief compared to conservative treatment. If symptomatic relief is the patient's primary concern, a conservative approach is preferred, whilst surgical intervention will decrease the likelihood of recurrence.

There was no difference in glycemic control or pregnancy outcomes in women using CSII or MDI managed in a multidisciplinary setting. Greater adjustments are needed to ISFs with CSII therapy. Overall, these data do not support recommending CSII in pregnancy with potentially higher patient and staff demands and costs and lack of improvement in HbA1c and pregnancy outcomes.

BACKGROUND Primary care plays a key role in management of type 2 diabetes. SGLT2 inhibitors have been demonstrated to also reduce hospitalisation and cardiac and renal complications. Tools that optimise management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today is software which facilitates clinical decision support and quality improvement activities. OBJECTIVE The study aims to explore the barriers and enablers to implementation of an SGLT2 inhibitor module within Future Health Today software. METHODS Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve SGLT2 inhibitor prescribing. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. RESULTS Sixteen interviews were completed. The enablers included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement and knowledge of the clinical topic. CONCLUSIONS There is a recognised benefit for the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimisation of patient management of type 2 diabetes in primary care.